Champions Oncology, Inc. (FRA:2I3)

Champions Oncology Statistics

Total Valuation

FRA:2I3 has a market cap or net worth of EUR 71.16 million. The enterprise value is 67.41 million.

Market Cap	71.16M
Enterprise Value	67.41M

Important Dates

The next estimated earnings date is Friday, December 12, 2025.

Earnings Date	Dec 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	13.79M
Shares Outstanding	n/a
Shares Change (YoY)	+4.67%
Shares Change (QoQ)	+0.25%
Owned by Insiders (%)	26.58%
Owned by Institutions (%)	11.26%
Float	5.11M

Valuation Ratios

The trailing PE ratio is 27.58 and the forward PE ratio is 39.24.

PE Ratio	27.58
Forward PE	39.24
PS Ratio	1.43
PB Ratio	23.01
P/TBV Ratio	25.66
P/FCF Ratio	11.24
P/OCF Ratio	10.61
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.32, with an EV/FCF ratio of 10.65.

EV / Earnings	26.12
EV / Sales	1.38
EV / EBITDA	12.32
EV / EBIT	26.04
EV / FCF	10.65

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 1.68.

Current Ratio	0.93
Quick Ratio	0.87
Debt / Equity	1.68
Debt / EBITDA	0.93
Debt / FCF	0.82
Interest Coverage	111.48

Financial Efficiency

Return on equity (ROE) is 182.28% and return on invested capital (ROIC) is 23.16%.

Return on Equity (ROE)	182.28%
Return on Assets (ROA)	6.78%
Return on Invested Capital (ROIC)	23.16%
Return on Capital Employed (ROCE)	38.35%
Revenue Per Employee	233,440
Profits Per Employee	12,116
Employee Count	213
Asset Turnover	2.05
Inventory Turnover	n/a

Taxes

Income Tax	-71,684
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +38.89% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+38.89%
50-Day Moving Average	5.54
200-Day Moving Average	6.27
Relative Strength Index (RSI)	43.13
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.86

Income Statement

In the last 12 months, FRA:2I3 had revenue of EUR 49.72 million and earned 2.58 million in profits. Earnings per share was 0.19.

Revenue	49.72M
Gross Profit	24.10M
Operating Income	2.63M
Pretax Income	2.48M
Net Income	2.58M
EBITDA	3.99M
EBIT	2.63M
Earnings Per Share (EPS)	0.19

Balance Sheet

The company has 9.03 million in cash and 5.19 million in debt, giving a net cash position of 3.84 million.

Cash & Cash Equivalents	9.03M
Total Debt	5.19M
Net Cash	3.84M
Net Cash Per Share	n/a
Equity (Book Value)	3.09M
Book Value Per Share	0.22
Working Capital	-1.47M

Cash Flow

In the last 12 months, operating cash flow was 6.71 million and capital expenditures -380,277, giving a free cash flow of 6.33 million.

Operating Cash Flow	6.71M
Capital Expenditures	-380,277
Free Cash Flow	6.33M
FCF Per Share	n/a

Margins

Gross margin is 48.47%, with operating and profit margins of 5.29% and 5.19%.

Gross Margin	48.47%
Operating Margin	5.29%
Pretax Margin	4.99%
Profit Margin	5.19%
EBITDA Margin	8.02%
EBIT Margin	5.29%
FCF Margin	12.73%

Dividends & Yields

FRA:2I3 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.67%
Shareholder Yield	-4.67%
Earnings Yield	3.63%
FCF Yield	8.89%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:2I3 has an Altman Z-Score of 0.55 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.55
Piotroski F-Score	7